Headlines about The Medicines (NASDAQ:MDCO) have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. The Medicines earned a daily sentiment score of 0.02 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.6683724212889 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news articles that may have effected Accern’s rankings:
- Check side-effects of hay fever remedies and medicines before driving (edp24.co.uk)
- Illinois Senate OKs plan to allow cannabis-based medicines in school (ilnews.org)
- A gastroenterologist explains Russia’s convoluted pharmaceutical market, as federal officials adopt new ‘counter … (meduza.io)
- Meet The Entrepreneurs Pioneering The “Clean Medicine” Movement (forbes.com)
- The Patent Paradox In Brazil And Its Implications For Access To Medicines (ip-watch.org)
MDCO has been the topic of a number of research reports. Chardan Capital restated a “buy” rating and set a $85.00 target price on shares of The Medicines in a research report on Wednesday, January 24th. Jefferies Group restated a “buy” rating and set a $47.00 target price on shares of The Medicines in a research report on Friday, February 23rd. BidaskClub upgraded shares of The Medicines from a “sell” rating to a “hold” rating in a research report on Thursday, March 15th. Oppenheimer restated a “buy” rating on shares of The Medicines in a research report on Thursday, March 22nd. Finally, ValuEngine upgraded shares of The Medicines from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $50.00.
Shares of NASDAQ:MDCO opened at $31.97 on Friday. The company has a market capitalization of $2.35 billion, a P/E ratio of -3.81 and a beta of 0.67. The company has a debt-to-equity ratio of 9.70, a quick ratio of 2.52 and a current ratio of 2.56. The Medicines has a fifty-two week low of $24.45 and a fifty-two week high of $43.86.
The Medicines (NASDAQ:MDCO) last announced its quarterly earnings results on Wednesday, April 25th. The company reported ($0.77) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.03. The business had revenue of $7.71 million for the quarter, compared to the consensus estimate of $9.21 million. The Medicines had a negative net margin of 1,109.21% and a negative return on equity of 609.97%. The Medicines’s revenue for the quarter was down 55.8% on a year-over-year basis. During the same period last year, the company posted ($1.05) EPS. analysts forecast that The Medicines will post -3.51 EPS for the current fiscal year.
In related news, Director Armin M. Kessler sold 20,000 shares of the stock in a transaction that occurred on Monday, April 16th. The shares were sold at an average price of $28.71, for a total value of $574,200.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director William Crouse sold 7,500 shares of the stock in a transaction that occurred on Wednesday, March 21st. The shares were sold at an average price of $32.26, for a total transaction of $241,950.00. Following the completion of the sale, the director now owns 60,633 shares in the company, valued at $1,956,020.58. The disclosure for this sale can be found here. Company insiders own 8.22% of the company’s stock.
The Medicines Company Profile
The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States.
Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.